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BACKGROUND
Pertuzumab increases the rate of pathological complete response in the preoperative 
context and increases overall survival among patients with metastatic disease when 
it is added to trastuzumab and chemotherapy for the treatment of human epidermal 
growth factor receptor 2 (HER2)–positive breast cancer. In this trial, we investigated 
whether pertuzumab, when added to adjuvant trastuzumab and chemotherapy, im-
proves outcomes among patients with HER2-positive early breast cancer.
METHODS
We randomly assigned patients with node-positive or high-risk node-negative HER2-
positive, operable breast cancer to receive either pertuzumab or placebo added to 
standard adjuvant chemotherapy plus 1 year of treatment with trastuzumab. We 
assumed a 3-year invasive-disease–free survival rate of 91.8% with pertuzumab 
and 89.2% with placebo.
RESULTS
In the trial population, 63% of the patients who were randomly assigned to receive 
pertuzumab (2400 patients) or placebo (2405 patients) had node-positive disease 
and 36% had hormone-receptor–negative disease. Disease recurrence occurred in 
171 patients (7.1%) in the pertuzumab group and 210 patients (8.7%) in the placebo 
group (hazard ratio, 0.81; 95% confidence interval [CI], 0.66 to 1.00; P = 0.045). The 
estimates of the 3-year rates of invasive-disease–free survival were 94.1% in the 
pertuzumab group and 93.2% in the placebo group. In the cohort of patients with 
node-positive disease, the 3-year rate of invasive-disease–free survival was 92.0% 
in the pertuzumab group, as compared with 90.2% in the placebo group (hazard 
ratio for an invasive-disease event, 0.77; 95% CI, 0.62 to 0.96; P = 0.02). In the cohort 
of patients with node-negative disease, the 3-year rate of invasive-disease–free sur-
vival was 97.5% in the pertuzumab group and 98.4% in the placebo group (hazard 
ratio for an invasive-disease event, 1.13; 95% CI, 0.68 to 1.86; P = 0.64). Heart failure, 
cardiac death, and cardiac dysfunction were infrequent in both treatment groups. 
Diarrhea of grade 3 or higher occurred almost exclusively during chemotherapy and 
was more frequent with pertuzumab than with placebo (9.8% vs. 3.7%).
CONCLUSIONS
Pertuzumab significantly improved the rates of invasive-disease–free survival among 
patients with HER2-positive, operable breast cancer when it was added to trastuzumab 
and chemotherapy. Diarrhea was more common with pertuzumab than with placebo. 
(Funded by F. Hoffmann–La Roche/Genentech; APHINITY ClinicalTrials.gov num-
ber, NCT01358877.)
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Combining trastuzumab, an anti–human epidermal growth factor receptor 2 (HER2) monoclonal antibody, with ad-
juvant chemotherapy has markedly improved out-
comes among patients with HER2-positive early 
breast cancer, reducing the risk of disease recur-
rence and death.1-3 The combination of chemo-
therapy and 1 year of treatment with trastuzumab 
is the current standard of care for this patient 
population.4
Pertuzumab is a humanized monoclonal anti-
body that has mechanisms of action complemen-
tary to those of trastuzumab, binding to different 
domains.5,6 Trastuzumab binds close to the trans-
membrane domain, inhibiting HER2 dimerization, 
whereas pertuzumab binds to the dimerization 
domain, inhibiting HER2 heterodimerization with 
other HER family receptors. Both antibodies induce 
antibody-dependent cell-mediated cytotoxicity.
In patients with HER2-positive metastatic breast 
cancer, pertuzumab added to trastuzumab and 
docetaxel has been shown to significantly prolong 
both progression-free survival and overall sur-
vival.7,8 Higher frequencies of grade 3 or 4 febrile 
neutropenia, any neutropenia, and diarrhea were 
associated with the addition of pertuzumab, but 
the rate of cardiac adverse events was similar to 
that in the control group.9 Dual HER2 blockade 
with pertuzumab and trastuzumab is the standard 
of care as first-line therapy for patients with ad-
vanced HER2-positive disease.
As part of a neoadjuvant regimen, pertuzumab 
added to trastuzumab plus docetaxel was shown 
to significantly increase the rate of pathological 
complete response, which led to its approval by 
health authorities.10,11 Here we report the results 
of adding pertuzumab or placebo to chemothera-
py plus trastuzumab as adjuvant treatment for 
patients with HER2-positive early breast cancer.
Me thods
Trial Design
We conducted a prospective, two-group, random-
ized, multicenter, multinational, double-blind, 
placebo-controlled trial. Eligible patients were ran-
domly assigned to receive chemotherapy and 1 year 
of treatment with trastuzumab plus pertuzumab 
or chemotherapy and 1 year of treatment with 
trastuzumab plus placebo (Fig. S1 in the Supple-
mentary Appendix, available with the full text of 
this article at NEJM.org).
Trial Oversight
The trial, which involved 549 centers across 
43 countries, was designed by the Breast Interna-
tional Group in collaboration with the sponsor, 
Hoffmann–La Roche/Genentech, and was con-
ducted under the auspices of an independent data 
and safety monitoring committee. Data were gath-
ered and analyzed at the Breast European Adjuvant 
Study Team data center. All parties involved in the 
trial were unaware of the treatment assignments. 
The sponsor had no access to the full database 
before the release of the results by the steering 
committee. The first draft of the manuscript was 
written by the first author. The steering committee 
vouches for the accuracy and completeness of the 
data and the fidelity of the trial to the protocol, 
available at NEJM.org. No one who is not an au-
thor contributed to writing the manuscript. The 
institutional review board at each participating 
center approved the trial protocol. All patients 
provided written informed consent.
Patients and Eligibility Criteria
Patients with nonmetastatic, adequately excised, 
histologically confirmed invasive HER2-positive 
breast cancer were eligible for participation in the 
trial. HER2 positivity had to be centrally confirmed 
and was defined as an immunohistochemical 
score of 3+ (scores range from 0 to 3+, with 
higher scores indicating higher staining intensity) 
in more than 10% of immunoreactive cells or 
amplification of ERBB2 (the gene encoding HER2) 
by in situ hybridization.12 Patients with synchro-
nous bilateral invasive disease were eligible if 
both lesions were HER2-positive. Eligible patients 
had to have either node-positive disease or node-
negative disease with a tumor diameter greater 
than 1.0 cm. Patients with node-negative tumors 
between 0.5 and 1.0 cm in diameter were initially 
eligible if at least one of the following high-risk 
features was present: histologic or nuclear grade 3, 
negativity for estrogen and progesterone receptors, 
or age younger than 35 years. Under a protocol 
amendment that was added after 3655 patients 
had undergone randomization, patients with node-
negative disease were no longer eligible for enroll-
ment, in order to enroll a patient population with 
the nodal-status distribution that had been antici-
pated when the trial was designed. The interval 
between definitive breast surgery and the first 
chemotherapy dose had to be within 8 weeks. The 
baseline left ventricular ejection fraction had to 
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be at least 55%. Patients with any of the following 
conditions or previous treatments were ineligible: 
previous invasive breast cancer; nonbreast cancer 
within 5 years before randomization, with the ex-
ception of carcinoma in situ of the cervix or colon, 
melanoma in situ, and skin basal-cell or squa-
mous-cell carcinomas; any previous chemotherapy 
or radiotherapy for cancer; any previous anti-HER2 
therapy or other previous anticancer biologic ther-
apy or immunotherapy; and concurrent serious 
diseases interfering with planned treatment, espe-
cially serious cardiac or cardiovascular disease or 
severe pulmonary conditions.
Randomization and Treatment
A Web-based system was used to collect patient 
screening information and to randomly assign 
eligible patients in a 1:1 ratio to one of the two 
treatment groups. A permuted-blocks randomiza-
tion procedure was used, with patients stratified 
according to nodal status, adjuvant chemotherapy 
regimen, hormone-receptor status, geographic re-
gion, and protocol version.
Participants received pertuzumab or placebo 
(840 mg as a loading dose administered intrave-
nously, followed by 420 mg intravenously every 
3 weeks) and trastuzumab (8 mg per kilogram 
of body weight intravenously as a loading dose, 
followed by 6 mg per kilogram intravenously 
every 3 weeks), both beginning at the first cycle 
of taxane therapy and continuing for a maximum 
of 18 cycles within 1 year. Anti-HER2 treatment 
was given in combination with chemotherapy 
according to one of the following schedules: 3 or 
4 cycles (every 3 weeks) of 5-fluorouracil plus 
either epirubicin or doxorubicin plus cyclophos-
phamide, followed by 3 or 4 cycles (every 3 weeks) 
of docetaxel or 12 weekly cycles of paclitaxel; 
4 cycles (every 3 weeks or every 2 weeks) of cyclo-
phosphamide plus either doxorubicin or epirubicin, 
followed by either 4 cycles (every 3 weeks) of 
docetaxel or 12 weekly cycles of paclitaxel; or 
6 cycles (every 3 weeks) of docetaxel plus carbo-
platin. Patients with hormone-receptor–positive 
tumors received standard endocrine therapy start-
ing at the end of chemotherapy; the endocrine 
therapy was planned to continue for at least 5 years. 
Radiotherapy was given as clinically indicated at 
the end of chemotherapy and concomitantly with 
anti-HER2 treatment.
A physical examination and an assessment of 
safety and concomitant medications were con-
ducted every 3 months during the first 24 months 
of participation in the trial and every 6 months 
thereafter. Cardiac monitoring, including an as-
sessment of the left ventricular ejection fraction, 
was performed every 3 months during treatment, 
every 6 months up to month 36, and yearly there-
after. Hematologic and liver-function tests were 
conducted every 6 months up to month 60 and 
then annually for a total of 10 years thereafter. 
Other investigations were recommended only when 
clinically indicated.
Statistical Analysis
Primary End Point
The primary end point, invasive-disease–free sur-
vival, was defined as the time from randomiza-
tion until the date of the first occurrence of one 
of the following events (hereafter referred to as 
invasive-disease events): recurrence of ipsilateral 
invasive breast tumor, recurrence of ipsilateral 
locoregional invasive disease, a distant disease 
recurrence, contralateral invasive breast cancer, 
or death from any cause. Data from patients with-
out documented events were censored at the date 
the patient was last known to be disease-free. 
This definition of invasive-disease–free survival 
(which excludes second primary nonbreast cancer 
as events) differs from the standardized defini-
tions for efficacy end points (STEEP) definition.13
The stratified log-rank test was used to com-
pare the rates of invasive-disease–free survival 
between the two treatment groups. The Kaplan–
Meier approach was used to estimate 3-year per-
centages for each treatment group. The stratified 
Cox proportional-hazards model was used to es-
timate the hazard ratio and its 95% confidence 
interval. The primary analysis was based on the 
intention-to-treat population. The trial was de-
signed to have 80% power to detect a hazard ratio 
of 0.75 at a 5%, two-sided significance level. A 
3-year rate of invasive-disease–free survival of 
89.2% was assumed for the placebo group, on 
the basis of the results of the Breast Cancer In-
ternational Research Group 006 trial,3 and a rate 
of 91.8% was assumed for the pertuzumab group, 
with approximately 379 events required for the 
primary analysis.
Secondary End Points
The secondary end points included overall sur-
vival, disease-free survival (including noninvasive 
breast cancers), invasive-disease–free survival (in-
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cluding second primary nonbreast cancer, per the 
STEEP definition), relapse-free interval and dis-
tant-relapse–free interval, safety, and health-relat-
ed quality of life. The final (event-driven) overall 
survival analysis is planned to be conducted when 
640 deaths have occurred. Three interim overall 
survival analyses are planned, with the first re-
ported here at an adjusted two-sided significance 
level of 0.00001 to control the overall alpha level 
at 0.05.
Cardiac Safety
Patients who received at least one dose of study 
treatment were included in safety analyses, accord-
ing to the treatment that was actually received. The 
primary cardiac end point was defined as heart 
failure of New York Heart Association (NYHA) 
class III or IV and a substantial decrease in left 
ventricular ejection fraction, defined as a decrease 
of at least 10 percentage points from baseline and 
to below 50%, or cardiac death. Cardiac death was 
identified by the cardiac advisory board for the 
trial in accordance with a prospective definition.
A secondary cardiac end point was an asymp-
tomatic or mildly symptomatic (NYHA class II) 
substantial decrease in left ventricular ejection 
fraction, as assessed by multiple-gated acquisition 
(MUGA) scanning or echocardiography, confirmed 
by a second left ventricular ejection fraction assess-
ment conducted within approximately 3 weeks 
also showing a substantial decrease or as con-
firmed by the cardiac advisory board. Health-
related quality of life was measured with the use 
of the European Organisation for Research and 
Treatment of Cancer (EORTC) QLQ-C30 question-
naire.
R esult s
Patient Characteristics and Adherence to 
Anti-HER2 Treatment
From November 2011 through August 2013, a 
total of 4805 patients were randomly assigned to 
receive chemotherapy and trastuzumab plus either 
pertuzumab (2400 patients) or placebo (2405 pa-
tients) (Fig. S2 in the Supplementary Appendix). 
The baseline characteristics of the patients were 
balanced between the two groups, with 63% hav-
ing node-positive disease and 36% having hor-
mone-receptor–negative disease (Table 1, and Table 
S1 in the Supplementary Appendix). The median 
follow-up period in the intention-to-treat popu-
lation was 45.4 months (48.3 months for patients 
with node-negative disease and 44.5 months for 
patients with node-positive disease).
One year of treatment was completed by 84.5% 
of the patients in the pertuzumab group and 87.4% 
of the patients in the placebo group. Treatment 
was discontinued for safety reasons by 7.8% of the 
patients in the pertuzumab group and 6.4% of 
the patients in the placebo group (Table S5 in the 
Supplementary Appendix).
Efficacy
In the analysis of the primary end point, the ad-
dition of pertuzumab was found to be associated 
with a significantly higher rate of invasive-disease–
free survival than placebo (Fig. 1A). In total, inva-
sive-disease events were reported in 171 patients 
(7.1%) in the pertuzumab group and 210 patients 
(8.7%) in the placebo group. The 3-year rate of 
invasive-disease–free survival was 94.1% in the 
pertuzumab group and 93.2% in the placebo 
group, with a hazard ratio for an invasive-disease 
event of 0.81 (95% confidence interval [CI], 0.66 
to 1.00; P = 0.045) in favor of pertuzumab. Distant 
recurrence occurred as the first invasive-disease 
event in 112 patients (4.7%) in the pertuzumab 
group and 139 patients (5.8%) in the placebo 
group, whereas the numbers of patients with 
locoregional recurrences were 26 (1.1%) and 34 
(1.4%), respectively. Central nervous system metas-
tases occurred as the first invasive-disease event 
in 1.9% of the patients in the pertuzumab group 
and 1.8% of the patients in the placebo group 
(Table 2). A visceral or central nervous system site 
was more common than bone as the site of first 
distant recurrence (Table S3 in the Supplementary 
Appendix). When the occurrence of a second pri-
mary nonbreast cancer was included in the analy-
sis of invasive-disease–free survival, the number 
of patients with an event increased to 189 in the 
pertuzumab group and 230 in the placebo group, 
resulting in a significant between-group difference 
(hazard ratio, 0.82; 95% CI, 0.68 to 0.99; P = 0.04) 
(Table S4 in the Supplementary Appendix).
The effect of pertuzumab on invasive-dis-
ease–free survival was homogeneous among the 
different patient subgroups (Fig. 2). Preplanned 
subgroup analysis revealed that the number of 
invasive-disease events was low among patients 
with node-negative disease (32 patients [3.6%] in 
the pertuzumab group and 29 patients [3.2%] in 
the placebo group), and no treatment effect was 
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detectable (hazard ratio, 1.13; 95% CI, 0.68 to 1.86; 
P = 0.64) (Fig. 1B). In the cohort of patients with 
node-positive disease, 139 patients (9.2%) in the 
pertuzumab group and 181 patients (12.1%) in 
the placebo group had invasive-disease events; the 
3-year rate of invasive-disease–free survival was 
92.0% in the pertuzumab group and 90.2% in 
the placebo group (hazard ratio for an invasive-
disease event, 0.77; 95% CI, 0.62 to 0.96; P = 0.02) 
(Fig. 1C). In the cohort of patients with hormone-
receptor–negative tumors, 71 patients (8.2%) in 
the pertuzumab group and 91 patients (10.6%) in 
the placebo group had invasive-disease events 
(hazard ratio, 0.76; 95% CI, 0.56 to 1.04; P = 0.08); 
the 3-year rate of invasive-disease–free survival 
was 92.8% in the pertuzumab group and 91.2% 
in the placebo group (Fig. 2, and Fig. S3 in the 
Supplementary Appendix). In the cohort of patients 
with hormone-receptor–positive disease, 100 pa-
tients (6.5%) in the pertuzumab group and 119 
patients (7.7%) in the placebo group had invasive-
disease events (hazard ratio, 0.86; 95% CI, 0.66 
Characteristic
Pertuzumab Group 
(N = 2400)
Placebo Group 
(N = 2404)
Nodal status — no. of patients (%)
0 positive nodes and tumor ≤1 cm* 90 (3.8) 84 (3.5)
0 positive nodes and tumor >1 cm* 807 (33.6) 818 (34.0)
1–3 positive nodes 907 (37.8) 900 (37.4)
≥4 positive nodes 596 (24.8) 602 (25.0)
Adjuvant chemotherapy regimen — no. of patients (%)†
Anthracycline-containing regimen 1865 (77.7) 1877 (78.1)
Non–anthracycline-containing regimen 535 (22.3) 527 (21.9)
Hormone-receptor status — no. of patients (%)‡
Negative 864 (36.0) 858 (35.7)
Positive 1536 (64.0) 1546 (64.3)
Protocol version — no. of patients (%)*
Protocol A 1828 (76.2) 1827 (76.0)
Protocol B 572 (23.8) 577 (24.0)
Age — no. of patients (%)
<40 yr 326 (13.6) 327 (13.6)
40–64 yr 1759 (73.3) 1784 (74.2)
≥65 yr 315 (13.1) 293 (12.2)
Pathological tumor size — no. of tumors/total no. (%)§
0 to <2 cm 978/2400 (40.8) 948/2405 (39.4)
2 to <5 cm 1275/2400 (53.1) 1283/2405 (53.3)
≥5 cm 147/2400 (6.1) 174/2405 (7.2)
*  Under the original protocol (protocol A), patients with node-negative tumors were initially eligible for participation in 
the trial if at least one of the following high-risk features was present: histologic or nuclear grade 3, negativity for estro-
gen and progesterone receptors, or age younger than 35 years. Under protocol B, which included an amendment that 
was added after 3655 patients had undergone randomization, patients with node-negative disease were no longer eligi-
ble for enrollment, in order to enroll a patient population with the nodal-status distribution that had been anticipated 
when the trial was designed.
†  The chemotherapy regimen that was planned at the time of randomization is shown; the regimen that patients received 
may have differed.
‡  Hormone-receptor status was based on the test results determined by a central laboratory, which repeated the testing 
that was performed locally at each participating center. Negative denotes estrogen-receptor–negative and progesterone-
receptor–negative; positive denotes estrogen-receptor–positive, progesterone-receptor–positive, or both.
§  Patients with bilateral tumors have pathological characteristics reported for both tumors; therefore, pathological tumor 
characteristics are summarized at the tumor level.
Table 1. Demographic and Baseline Disease Characteristics of the Patients.
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to 1.13; P = 0.28); the 3-year rate of invasive-dis-
ease–free survival was 94.8% in the pertuzumab 
group and 94.4% in the placebo group (Fig. 2, 
and Fig. S3 in the Supplementary Appendix). The 
tests for interaction of the treatment effect were 
not significant for any of the patient subgroups 
considered, including those based on nodal sta-
tus and hormone-receptor status (Fig. 2). On the 
basis of the absolute risk of avoiding an invasive-
disease event by 3 years, the numbers needed to 
treat are 112 for the overall population, 56 for 
the node-positive population, and 63 for hor-
mone-receptor–negative population.
A total of 169 patients died, 80 (3.3%) in the 
pertuzumab group and 89 (3.7%) in the placebo 
group. There was no significant treatment effect 
with regard to mortality at this first interim over-
all survival analysis (hazard ratio, 0.89; 95% CI, 
0.66 to 1.21; P = 0.47) (Fig. S5 in the Supplemen-
tary Appendix). Death without a previous invasive-
disease event occurred in 28 patients in the pertu-
zumab group and 26 patients in the placebo 
group (Table 2).
Safety
The safety analysis populations included 2364 
patients who were treated with at least one dose 
of pertuzumab and 2405 patients who received 
study medication (including chemotherapy or 
trastuzumab) but no pertuzumab (placebo group) 
(Table 3). The adverse-event profile during the 
treatment period was generally balanced between 
the two groups.
Primary cardiac events occurred in 17 patients 
(0.7%) in the pertuzumab group and in 8 pa-
tients (0.3%) in the placebo group (95% CI of the 
treatment difference, 0.0 to 0.8 percentage points); 
15 patients in the pertuzumab group and 6 pa-
tients in the placebo group had NYHA class III 
or IV heart failure and a substantial decrease in 
left ventricular ejection fraction, and 2 patients 
in each group died from cardiac causes (Table 3). 
In the pertuzumab group, a primary cardiac event 
occurred in 15 patients (0.8%) in the anthracy-
cline cohort and 2 patients (0.4%) in the non-
anthracycline cohort (Table S6 in the Supplemen-
tary Appendix). At the time of the clinical cutoff, 
7 events in the pertuzumab group and 4 events 
in the placebo group had resolved, per investiga-
tor assessment and data on left ventricular ejec-
tion fraction (details not shown). Secondary car-
diac events occurred in 64 patients (2.7%) in the 
Figure 1. Kaplan–Meier Plot of Invasive-Disease–free Survival.
Invasive-disease–free survival was defined as the time from randomization 
until the date of the first occurrence of one of the following invasive-dis-
ease events: recurrence of ipsilateral invasive breast tumor, recurrence of 
ipsilateral locoregional invasive disease, a distant disease recurrence, con-
tralateral invasive breast cancer, or death from any cause.
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pertuzumab group and 67 patients (2.8%) in the 
placebo group (95% CI of the treatment differ-
ence, −1.0 to 0.9 percentage points) (Table 3).
Diarrhea, anemia, and neutropenia were the 
most common (in >5% of patients) grade 3 or 
higher adverse events reported in the trial (Ta-
ble 3). The largest absolute difference between the 
treatment groups was found for diarrhea (9.8% in 
the pertuzumab group and 3.7% in the placebo 
group). During targeted therapy alone, after ces-
sation of chemotherapy, the incidence of grade 3 
or higher diarrhea was 0.5% in the pertuzumab 
group and 0.2% in the placebo group (Table S7 
in the Supplementary Appendix). The frequencies 
of grade 3 or higher diarrhea were lower in the 
anthracycline cohort (with anti-HER2 treatment 
started after anthracycline) than in the nonan-
thracycline cohort (Table S6 in the Supplementary 
Appendix). The largest differences between the 
treatment groups for all grades of adverse events 
were found for diarrhea (71.2% with pertuzumab 
and 45.2% with placebo) and rash (25.8% with 
pertuzumab and 20.3% with placebo) (details not 
shown). Baseline functional quality-of-life scores 
were similar between the treatment groups and 
remained stable during treatment, except for a 
temporary clinically meaningful decrease at the 
end of taxane treatment (Fig. S6 in the Supple-
mentary Appendix).
Discussion
The addition of pertuzumab to chemotherapy and 
trastuzumab as adjuvant treatment improved out-
comes among patients with HER2-positive early 
breast cancer. A treatment effect was most de-
tectable among patients who were at higher risk 
for relapse because of lymph-node involvement 
or hormone-receptor negativity, but the effect was 
statistically homogeneous throughout all sub-
groups. There were no new safety issues noted, 
but diarrhea was more common in the pertu-
zumab group than in the placebo group.7,10
The hazard ratio of 0.81 in this adjuvant con-
text must be weighed against the absolute risk of 
disease recurrence. It should be noted that the 
3-year invasive-disease–free survival rate of 93.2% 
in the placebo group was higher than our prospec-
tively assumed rate of 89.2%, and therefore it took 
longer than expected to reach the required num-
ber of events for the primary analysis. The median 
period of follow-up for this primary analysis was 
45.4 months, which might be too short for a full 
assessment of the effect size, especially in the co-
horts of patients with hormone-receptor–positive 
or node-negative disease. Subsequent analyses are 
planned in accordance with the trial protocol, with 
up to 10 years of minimum follow-up and the 
next analysis 2.5 years after this primary analysis.
Evaluations of patient benefit must always re-
late the magnitude of the effect to potential side 
effects. Pertuzumab was associated with a higher 
rate of diarrhea that was generally mild (grade 1 
or 2). The rate of treatment discontinuation due to 
adverse events was 1.1 percentage points higher 
with pertuzumab than with placebo. The posi-
tive results of our trial are consistent with those 
of the neoadjuvant NeoSphere trial, although the 
two trials did not use the same chemotherapy 
regimens. The addition of pertuzumab to trastu-
zumab–docetaxel neoadjuvant treatment for 12 
weeks in the randomized, multicenter, open-label 
NeoSphere trial resulted in a significant increase 
in the pathological complete response rate, from 
29.0% to 45.8%.10 The NeoSphere trial showed a 
numerically higher 5-year rate of progression-free 
survival among patients receiving only 12 weeks 
of pertuzumab than among patients receiving 
trastuzumab alone (hazard ratio for progression or 
death, 0.69; 95% CI, 0.34 to 1.40).11 The results 
seen in studies of dual HER2 blockade in the neo-
adjuvant context have not always been in concor-
Event
Pertuzumab Group 
(N = 2400)
Placebo Group 
(N = 2404)
no. of patients (%)
Any invasive-disease event 171 (7.1) 210 (8.7)
Category of first invasive-disease 
event
Distant recurrence 112 (4.7) 139 (5.8)
CNS metastases 45 (1.9) 44 (1.8)
Locoregional recurrence 26 (1.1) 34 (1.4)
Contralateral breast cancer 5 (0.2) 11 (0.5)
Death without previous event 28 (1.2) 26 (1.1)
*  Patients who had an additional invasive-disease event within 61 days of their 
first event are reported in the category according to the following hierarchy: 
distant recurrence, locoregional recurrence, contralateral breast cancer, and 
death without a previous event. A total of 38 additional patients (18 in the 
pertuzumab group and 20 in the placebo group) had an invasive-disease 
event under the standardized definitions for efficacy end points (STEEP) defi-
nition, which includes second primary nonbreast cancer. CNS denotes central 
nervous system.
Table 2. Site of First Invasive-Disease Event.*
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dance with the results seen when it is used as ad-
juvant therapy.14
Our trial has several strengths and limitations. 
It is a large, adequately powered, double-blind, 
placebo-controlled, phase 3 trial. The protocol 
amendment to limit the number of patients with 
node-negative disease and increase the sample size 
was implemented during the recruitment phase, in 
order to yield a patient population with the nodal-
status distribution that had been anticipated when 
the study was designed. The reasons for the high-
er-than-initially-foreseen enrollment of patients 
with node-negative disease remain unclear. Be-
cause only 1 year of pertuzumab treatment was 
investigated in this trial, the effectiveness of other 
treatment durations remains unknown. Ongoing 
studies are exploring whether after 6 months of 
neoadjuvant treatment with pertuzumab, patients 
will require additional treatment after surgery 
(ClinicalTrials.gov numbers, NCT02131064 and 
NCT02132949).
In conclusion, we found that pertuzumab, when 
added to chemotherapy and trastuzumab, signifi-
cantly improved the rates of invasive-disease–free 
Event
Pertuzumab Group 
(N = 2364)
Placebo Group 
(N = 2405)
no. of patients (%)
Grade ≥3 adverse event 1518 (64.2) 1379 (57.3)
Neutropenia 385 (16.3) 377 (15.7)
Febrile neutropenia 287 (12.1) 266 (11.1)
Neutrophil count decreased 228 (9.6) 230 (9.6)
Diarrhea† 232 (9.8) 90 (3.7)
Anemia 163 (6.9) 113 (4.7)
Fatal adverse event‡ 18 (0.8) 20 (0.8)
Primary cardiac event§ 17 (0.7) 8 (0.3)
NYHA class III or IV heart failure and substantial decrease in LVEF¶ 15 (0.6) 6 (0.2)
Definite or probable cardiac death 2 (0.1) 2 (0.1)
Secondary cardiac event‖ 64 (2.7) 67 (2.8)
Identified automatically from LVEF assessments 50 (2.1) 47 (2.0)
Identified by cardiac advisory board 14 (0.6) 20 (0.8)
*  The summary of grade 3 or higher adverse events includes adverse events with onset from the first dose of any study 
treatment through 28 days after the final dose of study treatment. The incidence of all other grade 3 or higher adverse 
events was lower than 5% in both safety analysis population groups. A summary of adverse events according to che-
motherapy regimen is provided in Table S6 in the Supplementary Appendix. NYHA denotes New York Heart 
Association.
†  For patients with diarrhea, early intervention with loperamide as well as fluid and electrolyte replacement was to be 
considered. The taxane dose had to be reduced by one dose level if grade 3 diarrhea occurred or unresolved grade 2 di-
arrhea required a delay of the next chemotherapy cycle.
‡  The fatal adverse events according to body system were neoplasms (benign, malignant, and unspecified) (9 patients in 
the pertuzumab group and 8 patients in the placebo group); cardiac disorders (2 and 3); infections and infestations (1 
and 3); respiratory, thoracic, and mediastinal disorders (2 and 2); gastrointestinal disorders (0 and 3); injury, poison-
ing, and procedural complications (2 and 0); blood and lymphatic system disorders (1 and 0); metabolism and nutri-
tion disorders (1 and 0); nervous system disorders (1 and 0); and psychiatric disorders (0 and 1). One patient in the 
pertuzumab group had a fatal adverse event that was reported in both the nervous system disorders and the injury, 
poisoning, and procedural complications body-system categories.
§  Primary cardiac events are counted over the whole trial period, including post-treatment follow-up. The 95% confidence 
interval (with Hauck–Anderson correction) for the between-group difference was 0.0 to 0.8 percentage points.
¶  A substantial decrease in left ventricular ejection fraction (LVEF) is defined as a decrease of 10 or more percentage 
points, to a value lower than 50%.
‖  Secondary cardiac events are counted up to the date of recurrence or the end of post-treatment follow-up, whichever 
occurs earlier, and are counted only for patients who have not had a primary cardiac event. The 95% confidence inter-
val (with Hauck–Anderson correction) for the between-group difference was −1.0 to 0.9 percentage points.
Table 3. Summary of Adverse Events (Safety Analysis Population).*
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survival among patients with HER2-positive early 
breast cancer. Pertuzumab was associated with 
more toxic effects than placebo — mainly low-
grade diarrhea.
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